• Je něco špatně v tomto záznamu ?

Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss

J. Škrha, P. Bušek, J. Uhrová, P. Hrabal, K. Kmochová, M. Laclav, B. Bunganič, P. Frič,

. 2016 ; 17 (1) : 89-94. [pub] 20161215

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031183

BACKGROUND: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. METHODS: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. RESULTS: Significantly lower plasma concentrations of GIP were found in PDAC patients with new-onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1-104.7) and 28.8 (7.4-112.2) ng/L, p < 0.001); the same relationship was observed for PP (38.9 (10.2-147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p < 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new-onset diabetes/prediabetes and weight loss > 2 kg (p < 0.001). CONCLUSIONS: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031183
003      
CZ-PrNML
005      
20171103101642.0
007      
ta
008      
171025s2016 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pan.2016.12.004 $2 doi
035    __
$a (PubMed)28027898
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Škrha, Jan $u 3rd Department of Internal Medicine and Laboratory for Endocrinology and Metabolism, Prague, Czechia. Electronic address: jan.skrha@lf1.cuni.cz.
245    10
$a Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss / $c J. Škrha, P. Bušek, J. Uhrová, P. Hrabal, K. Kmochová, M. Laclav, B. Bunganič, P. Frič,
520    9_
$a BACKGROUND: The changes in gastrointestinal hormones associated with pancreatic ductal adenocarcinoma (PDAC) in patients with impaired glucoregulation have yet to be evaluated. The aim of this study was to determine plasma concentrations of selected gastrointestinal hormones in PDAC patients with and without diabetes and to compare them with levels found in Type 2 diabetic patients without cancer. METHODS: In this study we examined plasma concentrations of glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY), and cytokines leptin and adiponectin in 94 patients with histologically confirmed PDAC. Thirty-nine patients with Type 2 diabetes without PDAC and 29 healthy individuals with no evidence of acute or chronic diseases were examined as controls. RESULTS: Significantly lower plasma concentrations of GIP were found in PDAC patients with new-onset diabetes/prediabetes (n = 76), or in those with normal glucose regulation (n = 18), compared to patients with Type 2 diabetes without PDAC and controls (15.5 (3.7-64.5) or 6.5 (1.7-24.5) vs. 39.8 (15.1-104.7) and 28.8 (7.4-112.2) ng/L, p < 0.001); the same relationship was observed for PP (38.9 (10.2-147.9) or 28.1 (7.9-100.0) vs 89.1 (38.0-208.9) and 75.8 (30.1-190.6) ng/L, p < 0.01), respectively. The lowest levels of GIP and PP concentrations were found in PDAC patients with new-onset diabetes/prediabetes and weight loss > 2 kg (p < 0.001). CONCLUSIONS: We conclude that GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. In new onset diabetes especially if associated with weight loss, these changes may represent a new clue for the diagnosis of PDAC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a duktální karcinom pankreatu $x krev $x komplikace $x diagnóza $x patofyziologie $7 D021441
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a diabetes mellitus 2. typu $x krev $x komplikace $x patofyziologie $7 D003924
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a žaludeční inhibiční polypeptid $x krev $7 D005749
650    _2
$a glukagonu podobný peptid 1 $x krev $7 D052216
650    _2
$a porucha glukózové tolerance $x krev $x komplikace $x patofyziologie $7 D018149
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuropeptid Y $x krev $7 D009478
650    _2
$a nádory slinivky břišní $x krev $x komplikace $x diagnóza $x patofyziologie $7 D010190
650    _2
$a pankreatický polypeptid $x krev $7 D010191
650    _2
$a peptid YY $x krev $7 D019894
650    12
$a hmotnostní úbytek $7 D015431
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bušek, Petr $u Department of Biochemistry and Experimental Oncology, Prague, Czechia.
700    1_
$a Uhrová, Jana $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Hrabal, Petr $u Department of Pathology, University Military Hospital of the Czech Ministry of Health and 1st Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Kmochová, Klára $u Department of Internal Medicine, University Military Hospital of the Czech Ministry of Health and 1st Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Laclav, Martin $u Department of Internal Medicine, University Military Hospital of the Czech Ministry of Health and 1st Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Bunganič, Bohuš $u Department of Internal Medicine, University Military Hospital of the Czech Ministry of Health and 1st Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Frič, Přemysl $u Department of Internal Medicine, University Military Hospital of the Czech Ministry of Health and 1st Faculty of Medicine, Charles University, Prague, Czechia.
773    0_
$w MED00008752 $t Pancreatology official journal of the International Association of Pancreatology (IAP) ... [et al.] $x 1424-3911 $g Roč. 17, č. 1 (2016), s. 89-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28027898 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171103101736 $b ABA008
999    __
$a ok $b bmc $g 1254776 $s 992210
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 17 $c 1 $d 89-94 $e 20161215 $i 1424-3911 $m Pancreatology $n Pancreatology $x MED00008752
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

    Možnosti archivace